BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NxThera Adds $12.6M Series B


3/17/2011 9:05:55 AM

Minneapolis / St. Paul Business Journal -- Add NxThera Inc. to the list of Twin Cities med-tech startups that have recently landed capital from large publicly traded medical-device makers

NxThera, which is developing technology to treat enlarged prostates, announced Wednesday that it’s raised $12.6 million in venture capital. Leading the round: American Medical Systems Holdings Inc., a Minnetonka-based firm that makes devices for treating “pelvic health” problems, including incontinence and prostate conditions.

Big med-tech companies such as Medtronic Inc. have a long history of making so-called “strategic” investments in promising startups. The deals are often an indication that the big company wants to buy the startup — if all goes well.

While the trend isn’t entirely new, corporate venture-capital deals have lately become a bit of a hot topic in med-tech. That’s partly because dollars from traditional venture capitalists are harder to come by, making big companies an important source of early-stage funding. Also, the cost of developing new technologies is on the rise, so big med-tech firms can use investments in startups to access a new technology without having to take on all the risk of developing it on their own.

Other Twin Cities med-tech firms that have recently landed money from strategic investors include Cardiac Concepts and BridgePoint Medical Inc.

In its most recent round, NxThera also raised money from traditional venture-capital firms, including previous backers Arboretum Ventures, Aberdare Ventures and GDN Holdings. As part of the deal, Dr. Glen Nelson, chairman of GDN Holdings and a retired Medtronic vice chair, will join NxThera’s board.

Shoreview-based NxThera plans to use the capital to fund clinical trials. The company also is now pursuing regulatory approval to sell its technology in Europe.

NxThera’s device will help treat a condition called benign prostatic hypertrophy. Patients suffering from BPH have enlarged prostates, which causes patients to urinate more frequently or experience other urological problems. NxThera’s technology delivers a vapor to the prostate, reducing its size.




 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES